Navigation Links
PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Date:3/24/2008

ANNAPOLIS, Md., March 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2007 will be released on Monday, March 31, 2008.

PharmAthene management will be hosting a conference call to discuss its year end financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Monday, March 31, 2008 and will last approximately 30 minutes.

The dial-in number within the United States is 866-700-6979. The dial-in number for international callers is 617-213-8836. The participant passcode is 29363875.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. Eastern Time March 31, 2008 until approximately 11:50 p.m. Eastern Time April 30, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 76157985.

The conference call will also be webcast and can be accessed from the company's website at http://www.PharmAthene.com. A link to the webcast may be found on both the Home Page and also under the Investor Relations section of the website. The webcast will be available for 30 days, or until April 30, 2008.

About PharmAthene, Inc

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene to Delay Release of Full Year 2007 Financial Results
2. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
3. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
4. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
5. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
8. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Zansors announced today ... as issued by the U.S. Patent & Trademark Office (USPTO). The patent covers ... and health monitoring. This invention will be critical to the future of wearable ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD , ... deliver exclusive content to ReachMD learners. , The partnership, which launched in ...
(Date:3/29/2017)... OF PRUSSIA, Pa. , March 29, 2017 /PRNewswire/ ... to care, which is why CSL Behring awards Local ... work of rare disease patient groups. These groups tackle ... voices are heard on Capitol Hill and in statehouses ... funding cycle, the community-based grant was awarded to New ...
(Date:3/29/2017)... Inc. (NASDAQ: VRML), a bio-analytical solutions company focused ... the fourth quarter and full year ended December ... year for us with our first clinical utility ... reimbursement progress with Medicare, positive medical policy coverage ... cleared our 2 nd generation product Overa ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):